11/15
07:54 am
ifrx
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]
Low
Report
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]
11/15
07:51 am
ifrx
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
High
Report
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
11/13
02:07 am
ifrx
InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]
Medium
Report
InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]
11/11
10:22 am
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/8
07:30 am
ifrx
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31
07:30 am
ifrx
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
Low
Report
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
9/25
02:04 pm
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/25
07:30 am
ifrx
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
Low
Report
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
9/3
07:44 am
ifrx
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases [Yahoo! Finance]
Low
Report
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases [Yahoo! Finance]
9/3
07:30 am
ifrx
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
Low
Report
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
8/27
07:30 am
ifrx
InflaRx Announces Participation in September Investor Events
Low
Report
InflaRx Announces Participation in September Investor Events